GALNT2: A Potential Drug Target and Biomarker (G2590)

Target Name: GALNT2

NCBI ID: G2590

GALNT2

GALNT2: A Potential Drug Target and Biomarker

GALNT2, or Polypeptide N-acetylgalactosaminyltransferase 2, is a gene that encodes a protein involved in the biosynthesis of N-acetylgalactosamine (NAG), a key ingredient in the glycosylation of proteins and nucleic acids. NAG is synthesized from the amino acid Asp and the glucose molecule, and it functions as a structural component of various proteins, including insulin, growth factors, and neurotransmitters. Galnt2 is expressed in most tissues and cells of the body and is involved in the regulation of a wide range of cellular processes, including cell growth, differentiation, and inflammation.

GALNT2 has also been implicated in several diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these processes has led to its potential as a drug target or biomarker. In this article, we will explore the biology and potential applications of GALNT2 and its potential as a drug target.

The N-acetylgalactosaminyltransferase (Galnt) gene is located on chromosome 11q22 and encodes a protein with 218 amino acid residues. The protein has a molecular weight of approximately 21 kDa and a calculated pI of 5.5. Galnt is predominantly expressed in the brain and tests, and is also found in other tissues and cells, including muscle, heart, liver, and kidney.

GALNT is involved in the biosynthesis of N-acetylgalactosamine (NAG), a key ingredient in the glycosylation of proteins and nucleic acids. NAG is synthesized from the amino acids Asp and glucose, and it functions as a structural component of various proteins, including insulin , growth factors, and neurotransmitters. Galnt2 is responsible for transferring the acetyl group from Asp to the N-acetyl group on NAG.

In addition to its role in protein biosynthesis, Galnt2 is also involved in the regulation of cellular processes, including cell growth, differentiation, and inflammation. It has been shown to play a role in the development and progression of cancer, as well as in the pathogenesis of neurodegenerative diseases.

GALNT2 has also been implicated in several diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these processes has led to its potential as a drug target or biomarker. For example, GALNT2 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that targeting Galnt2 may be a promising strategy for the development of new cancer therapies.

In addition to its potential as a drug target, GALNT2 may also be used as a biomarker for certain diseases. For example, GALNT2 has been shown to be elevated in the brains of individuals with Alzheimer's disease, a neurodegenerative disorder. This suggests that targeting Galnt2 in this manner may be a promising strategy for the development of new treatments for Alzheimer's disease.

GALNT2 has also been shown to play a role in the regulation of cellular processes that are important for brain development and function. For example, GALNT2 has been shown to be involved in the regulation of the formation of new blood vessels in the brain, as well as in the regulation of neurotransmitter release from neurons. These processes are important for the development and maintenance of the brain, and may be relevant to the treatment of various neurological disorders.

In conclusion, GALNT2 is a gene that encodes a protein involved in the biosynthesis of N-acetylgalactosamine (NAG), a key ingredient in the glycosylation of proteins and nucleic acids. GALNT2 is primarily expressed in the brain and tests and is involved in

Protein Name: Polypeptide N-acetylgalactosaminyltransferase 2

Functions: Catalyzes the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue on the protein receptor. Has a broad spectrum of substrates for peptides such as EA2, Muc5AC, Muc1a, Muc1b. Probably involved in O-linked glycosylation of the immunoglobulin A1 (IgA1) hinge region. Involved in O-linked glycosylation of APOC-III, ANGPTL3 and PLTP. It participates in the regulation of HDL-C metabolism (PubMed:27508872, PubMed:32293671)

The "GALNT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GALNT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets